Topic 138
parp inhibitors ribose cancer parpi adp homologous brca1 poly inhibition repair recombination polymerase ovarian therapy dna inhibitor brca2 olaparib brca tumors rad51 cancers biology hr deficient mutated mutations lethality sensitivity platinum parp1 breast combination damage clinical pathway cytotoxicity treatment clinically targetable tumor veliparib depletion lines cells sensitive synthetic mutant response joining trials deficiency survival prostate atr rad51c lethal mek resistance serous pancreatic targeted double strand cisplatin upregulation patient increased mutation p53 agents relapsed patients vivo germline malignancies break therapies biomarker foci cgas alone toxic blocks pargi grade bard1 sting breaks parg hrd vitro tumours may poor inactivation radiation conversely parylation
27 items. Top items listed below.